#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=Materials and Methods
2-1	3-12	Materials	abstract	new	_	_
2-2	13-16	and	_	_	_	_
2-3	17-24	Methods	abstract	new	coref	11-34

#Text=This study was designed and developed according to the preferred reporting items for systematic reviews and meta-analysis ( PRISMA ) guidelines , an evidence-based set of minimum items for assessing the benefits and harms of a given healthcare intervention .
3-1	25-29	This	abstract[3]	new[3]	coref	17-5[125_3]
3-2	30-35	study	abstract[3]	new[3]	_	_
3-3	36-39	was	_	_	_	_
3-4	40-48	designed	_	_	_	_
3-5	49-52	and	_	_	_	_
3-6	53-62	developed	_	_	_	_
3-7	63-72	according	_	_	_	_
3-8	73-75	to	_	_	_	_
3-9	76-79	the	abstract[5]	new[5]	appos	3-23[10_5]
3-10	80-89	preferred	abstract[5]	new[5]	_	_
3-11	90-99	reporting	abstract|abstract[5]	new|new[5]	_	_
3-12	100-105	items	abstract[5]	new[5]	_	_
3-13	106-109	for	abstract[5]	new[5]	_	_
3-14	110-120	systematic	abstract[5]|abstract[6]|abstract[9]	new[5]|new[6]|new[9]	coref	20-15[157_9]
3-15	121-128	reviews	abstract[5]|abstract[6]|abstract[9]	new[5]|new[6]|new[9]	_	_
3-16	129-132	and	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-17	133-146	meta-analysis	abstract[5]|abstract|abstract[9]	new[5]|new|new[9]	appos	3-19
3-18	147-148	(	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-19	149-155	PRISMA	abstract[5]|abstract|abstract[9]	new[5]|giv|new[9]	_	_
3-20	156-157	)	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-21	158-168	guidelines	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-22	169-170	,	_	_	_	_
3-23	171-173	an	abstract[10]	giv[10]	coref	3-27[11_10]
3-24	174-188	evidence-based	abstract[10]	giv[10]	_	_
3-25	189-192	set	abstract[10]	giv[10]	_	_
3-26	193-195	of	abstract[10]	giv[10]	_	_
3-27	196-203	minimum	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
3-28	204-209	items	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
3-29	210-213	for	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
3-30	214-223	assessing	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
3-31	224-227	the	abstract[10]|abstract[11]|abstract[12]	giv[10]|giv[11]|new[12]	_	_
3-32	228-236	benefits	abstract[10]|abstract[11]|abstract[12]	giv[10]|giv[11]|new[12]	_	_
3-33	237-240	and	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
3-34	241-246	harms	abstract[10]|abstract[11]|abstract[13]	giv[10]|giv[11]|new[13]	_	_
3-35	247-249	of	abstract[10]|abstract[11]|abstract[13]	giv[10]|giv[11]|new[13]	_	_
3-36	250-251	a	abstract[10]|abstract[11]|abstract[13]|event[15]	giv[10]|giv[11]|new[13]|new[15]	coref	11-46[84_15]
3-37	252-257	given	abstract[10]|abstract[11]|abstract[13]|event[15]	giv[10]|giv[11]|new[13]|new[15]	_	_
3-38	258-268	healthcare	abstract[10]|abstract[11]|abstract[13]|organization|event[15]	giv[10]|giv[11]|new[13]|new|new[15]	_	_
3-39	269-281	intervention	abstract[10]|abstract[11]|abstract[13]|event[15]	giv[10]|giv[11]|new[13]|new[15]	_	_
3-40	282-283	.	_	_	_	_

#Text=2.1. Literature Search
4-1	284-288	2.1.	_	_	_	_
4-2	289-299	Literature	abstract|abstract[17]	new|new[17]	coref|coref	5-3[19_0]|14-7[103_17]
4-3	300-306	Search	abstract[17]	new[17]	_	_

#Text=We searched the literature in various electronic bibliographic databases ( PubMed/Medline , Embase , EBSCO , Cochrane databases , Lilacs , and Dialnet ) for all entries up until 30 March 2019 , without applying any publication age limitations .
5-1	307-309	We	person	acc	ana	9-3
5-2	310-318	searched	_	_	_	_
5-3	319-322	the	abstract[19]	giv[19]	coref	14-8[0_19]
5-4	323-333	literature	abstract[19]	giv[19]	_	_
5-5	334-336	in	abstract[19]	giv[19]	_	_
5-6	337-344	various	abstract[19]|abstract[20]	giv[19]|new[20]	appos	5-11[0_20]
5-7	345-355	electronic	abstract[19]|abstract[20]	giv[19]|new[20]	_	_
5-8	356-369	bibliographic	abstract[19]|abstract[20]	giv[19]|new[20]	_	_
5-9	370-379	databases	abstract[19]|abstract[20]	giv[19]|new[20]	_	_
5-10	380-381	(	_	_	_	_
5-11	382-396	PubMed/Medline	abstract|abstract[22]	giv|giv[22]	appos|appos	5-11[22_0]|5-13[0_22]
5-12	397-398	,	abstract[22]	giv[22]	_	_
5-13	399-405	Embase	abstract[22]|abstract	giv[22]|giv	appos	5-15
5-14	406-407	,	abstract[22]	giv[22]	_	_
5-15	408-413	EBSCO	abstract[22]|abstract	giv[22]|giv	appos	5-17[26_0]
5-16	414-415	,	abstract[22]	giv[22]	_	_
5-17	416-424	Cochrane	abstract[22]|person|abstract[26]	giv[22]|new|giv[26]	appos|coref	5-20[0_26]|20-16
5-18	425-434	databases	abstract[22]|abstract[26]	giv[22]|giv[26]	_	_
5-19	435-436	,	abstract[22]	giv[22]	_	_
5-20	437-443	Lilacs	abstract[22]|abstract	giv[22]|giv	appos	5-23
5-21	444-445	,	abstract[22]	giv[22]	_	_
5-22	446-449	and	abstract[22]	giv[22]	_	_
5-23	450-457	Dialnet	abstract[22]|abstract	giv[22]|giv	coref	7-7[42_0]
5-24	458-459	)	_	_	_	_
5-25	460-463	for	_	_	_	_
5-26	464-467	all	abstract[29]	new[29]	_	_
5-27	468-475	entries	abstract[29]	new[29]	_	_
5-28	476-478	up	abstract[29]	new[29]	_	_
5-29	479-484	until	_	_	_	_
5-30	485-487	30	time[30]	new[30]	_	_
5-31	488-493	March	time[30]|time	new[30]|new	_	_
5-32	494-498	2019	time[30]|time	new[30]|new	_	_
5-33	499-500	,	_	_	_	_
5-34	501-508	without	_	_	_	_
5-35	509-517	applying	_	_	_	_
5-36	518-521	any	abstract[35]	new[35]	_	_
5-37	522-533	publication	event|abstract[34]|abstract[35]	new|new[34]|new[35]	coref	17-14[128_34]
5-38	534-537	age	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-39	538-549	limitations	abstract[35]	new[35]	_	_
5-40	550-551	.	_	_	_	_

#Text=The reference lists of all the relevant articles were manually cross-referenced in order to identify any additional articles .
6-1	552-555	The	abstract[37]	new[37]	_	_
6-2	556-565	reference	abstract|abstract[37]	new|new[37]	_	_
6-3	566-571	lists	abstract[37]	new[37]	_	_
6-4	572-574	of	abstract[37]	new[37]	_	_
6-5	575-578	all	abstract[37]|abstract[38]	new[37]|new[38]	coref	6-16[39_38]
6-6	579-582	the	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-7	583-591	relevant	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-8	592-600	articles	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-9	601-605	were	_	_	_	_
6-10	606-614	manually	_	_	_	_
6-11	615-631	cross-referenced	_	_	_	_
6-12	632-634	in	_	_	_	_
6-13	635-640	order	_	_	_	_
6-14	641-643	to	_	_	_	_
6-15	644-652	identify	_	_	_	_
6-16	653-656	any	abstract[39]	giv[39]	coref	15-24[114_39]
6-17	657-667	additional	abstract[39]	giv[39]	_	_
6-18	668-676	articles	abstract[39]	giv[39]	_	_
6-19	677-678	.	_	_	_	_

#Text=The primary search terms used for all six databases were ‘ leucine ’ and ‘ sarcopenia ’ , as well as one of the following terms : ‘ older ’ , ‘ elderly ’ , ‘ disease ’ or ‘ trial ’ .
7-1	679-682	The	substance[41]	new[41]	coref	7-12[0_41]
7-2	683-690	primary	substance[41]	new[41]	_	_
7-3	691-697	search	event|substance[41]	new|new[41]	_	_
7-4	698-703	terms	substance[41]	new[41]	_	_
7-5	704-708	used	substance[41]	new[41]	_	_
7-6	709-712	for	substance[41]	new[41]	_	_
7-7	713-716	all	substance[41]|abstract[42]	new[41]|giv[42]	_	_
7-8	717-720	six	substance[41]|abstract[42]	new[41]|giv[42]	_	_
7-9	721-730	databases	substance[41]|abstract[42]	new[41]|giv[42]	_	_
7-10	731-735	were	_	_	_	_
7-11	736-737	‘	_	_	_	_
7-12	738-745	leucine	substance	giv	coref	7-24[46_0]
7-13	746-747	’	_	_	_	_
7-14	748-751	and	_	_	_	_
7-15	752-753	‘	_	_	_	_
7-16	754-764	sarcopenia	abstract	new	coref	11-6
7-17	765-766	’	_	_	_	_
7-18	767-768	,	_	_	_	_
7-19	769-771	as	_	_	_	_
7-20	772-776	well	_	_	_	_
7-21	777-779	as	_	_	_	_
7-22	780-783	one	abstract[45]	new[45]	_	_
7-23	784-786	of	abstract[45]	new[45]	_	_
7-24	787-790	the	abstract[45]|substance[46]	new[45]|giv[46]	coref	17-31[135_46]
7-25	791-800	following	abstract[45]|substance[46]	new[45]|giv[46]	_	_
7-26	801-806	terms	abstract[45]|substance[46]	new[45]|giv[46]	_	_
7-27	807-808	:	_	_	_	_
7-28	809-810	‘	_	_	_	_
7-29	811-816	older	_	_	_	_
7-30	817-818	’	_	_	_	_
7-31	819-820	,	_	_	_	_
7-32	821-822	‘	_	_	_	_
7-33	823-830	elderly	_	_	_	_
7-34	831-832	’	_	_	_	_
7-35	833-834	,	_	_	_	_
7-36	835-836	‘	_	_	_	_
7-37	837-844	disease	abstract	new	_	_
7-38	845-846	’	_	_	_	_
7-39	847-849	or	_	_	_	_
7-40	850-851	‘	_	_	_	_
7-41	852-857	trial	abstract	new	_	_
7-42	858-859	’	_	_	_	_
7-43	860-861	.	_	_	_	_

#Text=2.2. Inclusion and Exclusion Criteria
8-1	862-866	2.2.	_	_	_	_
8-2	867-876	Inclusion	abstract|abstract[50]|abstract[52]	new|new[50]|new[52]	ana|coref|coref	9-14[59_52]|15-35|15-35[118_50]
8-3	877-880	and	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-4	881-890	Exclusion	abstract[50]|abstract|abstract[52]	new[50]|new|new[52]	_	_
8-5	891-899	Criteria	abstract[52]	new[52]	_	_

#Text=To answer our research questions , we applied the following inclusion criteria to each of the considered manuscripts : ( 1 )
9-1	900-902	To	_	_	_	_
9-2	903-909	answer	_	_	_	_
9-3	910-913	our	person|abstract[55]	giv|new[55]	ana	9-7
9-4	914-922	research	abstract|abstract[55]	new|new[55]	_	_
9-5	923-932	questions	abstract[55]	new[55]	_	_
9-6	933-934	,	_	_	_	_
9-7	935-937	we	person	giv	ana	10-9
9-8	938-945	applied	_	_	_	_
9-9	946-949	the	abstract[58]	new[58]	coref	11-5[74_58]
9-10	950-959	following	abstract[58]	new[58]	_	_
9-11	960-969	inclusion	person|abstract[58]	new|new[58]	coref	17-22
9-12	970-978	criteria	abstract[58]	new[58]	_	_
9-13	979-981	to	_	_	_	_
9-14	982-986	each	abstract[59]	giv[59]	ana	10-1[0_59]
9-15	987-989	of	abstract[59]	giv[59]	_	_
9-16	990-993	the	abstract[59]|object[60]	giv[59]|new[60]	coref	14-3[101_60]
9-17	994-1004	considered	abstract[59]|object[60]	giv[59]|new[60]	_	_
9-18	1005-1016	manuscripts	abstract[59]|object[60]	giv[59]|new[60]	_	_
9-19	1017-1018	:	_	_	_	_
9-20	1019-1020	(	_	_	_	_
9-21	1021-1022	1	_	_	_	_
9-22	1023-1024	)	_	_	_	_

#Text=It was acknowledged as an original article ; we included experimental studies ( randomised and placebo-controlled trials ) and observational studies ( cohort , cross-sectional , and case-control studies ) ; ( 2 ) it was a full text published either in English , Portuguese , or Spanish ; ( 3 )
10-1	1025-1027	It	abstract	giv	ana	10-35
10-2	1028-1031	was	_	_	_	_
10-3	1032-1044	acknowledged	_	_	_	_
10-4	1045-1047	as	_	_	_	_
10-5	1048-1050	an	abstract[62]	new[62]	coref	11-33[81_62]
10-6	1051-1059	original	abstract[62]	new[62]	_	_
10-7	1060-1067	article	abstract[62]	new[62]	_	_
10-8	1068-1069	;	_	_	_	_
10-9	1070-1072	we	person	giv	ana	15-34
10-10	1073-1081	included	_	_	_	_
10-11	1082-1094	experimental	abstract[64]	new[64]	appos	10-14[65_64]
10-12	1095-1102	studies	abstract[64]	new[64]	_	_
10-13	1103-1104	(	_	_	_	_
10-14	1105-1115	randomised	abstract[65]	giv[65]	_	_
10-15	1116-1119	and	abstract[65]	giv[65]	_	_
10-16	1120-1138	placebo-controlled	abstract[65]	giv[65]	_	_
10-17	1139-1145	trials	abstract[65]	giv[65]	_	_
10-18	1146-1147	)	_	_	_	_
10-19	1148-1151	and	_	_	_	_
10-20	1152-1165	observational	abstract[66]	new[66]	_	_
10-21	1166-1173	studies	abstract[66]	new[66]	_	_
10-22	1174-1175	(	_	_	_	_
10-23	1176-1182	cohort	abstract[67]	new[67]	coref	12-1[85_67]
10-24	1183-1184	,	abstract[67]	new[67]	_	_
10-25	1185-1200	cross-sectional	abstract[67]	new[67]	_	_
10-26	1201-1202	,	abstract[67]	new[67]	_	_
10-27	1203-1206	and	abstract[67]	new[67]	_	_
10-28	1207-1219	case-control	abstract[67]	new[67]	_	_
10-29	1220-1227	studies	abstract[67]	new[67]	_	_
10-30	1228-1229	)	_	_	_	_
10-31	1230-1231	;	_	_	_	_
10-32	1232-1233	(	_	_	_	_
10-33	1234-1235	2	_	_	_	_
10-34	1236-1237	)	_	_	_	_
10-35	1238-1240	it	abstract	giv	coref	10-37[69_0]
10-36	1241-1244	was	_	_	_	_
10-37	1245-1246	a	abstract[69]	giv[69]	_	_
10-38	1247-1251	full	abstract[69]	giv[69]	_	_
10-39	1252-1256	text	abstract[69]	giv[69]	_	_
10-40	1257-1266	published	abstract[69]	giv[69]	_	_
10-41	1267-1273	either	abstract[69]|abstract[70]	giv[69]|new[70]	_	_
10-42	1274-1276	in	abstract[69]|abstract[70]	giv[69]|new[70]	_	_
10-43	1277-1284	English	abstract[69]|abstract[70]	giv[69]|new[70]	_	_
10-44	1285-1286	,	abstract[69]	giv[69]	_	_
10-45	1287-1297	Portuguese	abstract[69]	giv[69]	_	_
10-46	1298-1299	,	abstract[69]	giv[69]	_	_
10-47	1300-1302	or	abstract[69]	giv[69]	_	_
10-48	1303-1310	Spanish	abstract[69]|abstract	giv[69]|new	_	_
10-49	1311-1312	;	abstract[69]	giv[69]	_	_
10-50	1313-1314	(	abstract[69]	giv[69]	_	_
10-51	1315-1316	3	abstract[69]	giv[69]	_	_
10-52	1317-1318	)	abstract[69]	giv[69]	_	_

#Text=at least one of the sarcopenia criteria was measured : Muscular mass and/or muscular strength and/or physical performance ; ( 4 ) a description of how sarcopenia was evaluated was defined in the methods section ; ( 5 ) the concentration of leucine used in the intervention was specified or could be calculated .
11-1	1319-1321	at	_	_	_	_
11-2	1322-1327	least	_	_	_	_
11-3	1328-1331	one	abstract[72]	new[72]	_	_
11-4	1332-1334	of	abstract[72]	new[72]	_	_
11-5	1335-1338	the	abstract[72]|abstract[74]	new[72]|giv[74]	coref	15-34[120_74]
11-6	1339-1349	sarcopenia	abstract[72]|abstract|abstract[74]	new[72]|giv|giv[74]	coref	11-27
11-7	1350-1358	criteria	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
11-8	1359-1362	was	_	_	_	_
11-9	1363-1371	measured	_	_	_	_
11-10	1372-1373	:	_	_	_	_
11-11	1374-1382	Muscular	abstract[75]	new[75]	_	_
11-12	1383-1387	mass	abstract[75]	new[75]	_	_
11-13	1388-1394	and/or	_	_	_	_
11-14	1395-1403	muscular	abstract[76]	new[76]	_	_
11-15	1404-1412	strength	abstract[76]	new[76]	_	_
11-16	1413-1419	and/or	_	_	_	_
11-17	1420-1428	physical	abstract[77]	new[77]	coref	21-12[0_77]
11-18	1429-1440	performance	abstract[77]	new[77]	_	_
11-19	1441-1442	;	_	_	_	_
11-20	1443-1444	(	_	_	_	_
11-21	1445-1446	4	_	_	_	_
11-22	1447-1448	)	_	_	_	_
11-23	1449-1450	a	abstract[78]	new[78]	_	_
11-24	1451-1462	description	abstract[78]	new[78]	_	_
11-25	1463-1465	of	abstract[78]	new[78]	_	_
11-26	1466-1469	how	abstract[78]	new[78]	_	_
11-27	1470-1480	sarcopenia	abstract[78]|abstract	new[78]|giv	coref	17-39
11-28	1481-1484	was	abstract[78]	new[78]	_	_
11-29	1485-1494	evaluated	abstract[78]	new[78]	_	_
11-30	1495-1498	was	_	_	_	_
11-31	1499-1506	defined	_	_	_	_
11-32	1507-1509	in	_	_	_	_
11-33	1510-1513	the	abstract[81]	giv[81]	coref	16-9[123_81]
11-34	1514-1521	methods	abstract|abstract[81]	giv|giv[81]	coref	17-39[140_0]
11-35	1522-1529	section	abstract[81]	giv[81]	_	_
11-36	1530-1531	;	_	_	_	_
11-37	1532-1533	(	_	_	_	_
11-38	1534-1535	5	_	_	_	_
11-39	1536-1537	)	_	_	_	_
11-40	1538-1541	the	abstract[82]	new[82]	_	_
11-41	1542-1555	concentration	abstract[82]	new[82]	_	_
11-42	1556-1558	of	abstract[82]	new[82]	_	_
11-43	1559-1566	leucine	abstract[82]|substance[83]	new[82]|new[83]	coref	17-31[134_83]
11-44	1567-1571	used	abstract[82]|substance[83]	new[82]|new[83]	_	_
11-45	1572-1574	in	abstract[82]|substance[83]	new[82]|new[83]	_	_
11-46	1575-1578	the	abstract[82]|substance[83]|event[84]	new[82]|new[83]|giv[84]	_	_
11-47	1579-1591	intervention	abstract[82]|substance[83]|event[84]	new[82]|new[83]|giv[84]	_	_
11-48	1592-1595	was	_	_	_	_
11-49	1596-1605	specified	_	_	_	_
11-50	1606-1608	or	_	_	_	_
11-51	1609-1614	could	_	_	_	_
11-52	1615-1617	be	_	_	_	_
11-53	1618-1628	calculated	_	_	_	_
11-54	1629-1630	.	_	_	_	_

#Text=Studies performed in animals , case-report studies , letters to the Editor , abstracts from conferences , books , PhD theses were excluded .
12-1	1631-1638	Studies	abstract[85]|abstract[86]	giv[85]|giv[86]	coref|coref	12-1[86_85]|12-6[89_86]
12-2	1639-1648	performed	abstract[85]|abstract[86]	giv[85]|giv[86]	_	_
12-3	1649-1651	in	abstract[85]|abstract[86]	giv[85]|giv[86]	_	_
12-4	1652-1659	animals	abstract[85]|abstract[86]|animal	giv[85]|giv[86]|new	_	_
12-5	1660-1661	,	abstract[86]	giv[86]	_	_
12-6	1662-1673	case-report	abstract[86]|event|abstract[89]	giv[86]|new|giv[89]	coref	15-5[108_89]
12-7	1674-1681	studies	abstract[86]|abstract[89]	giv[86]|giv[89]	_	_
12-8	1682-1683	,	abstract[86]	giv[86]	_	_
12-9	1684-1691	letters	abstract[86]|abstract[90]	giv[86]|new[90]	_	_
12-10	1692-1694	to	abstract[86]|abstract[90]	giv[86]|new[90]	_	_
12-11	1695-1698	the	abstract[86]|abstract[90]|person[91]	giv[86]|new[90]|new[91]	_	_
12-12	1699-1705	Editor	abstract[86]|abstract[90]|person[91]	giv[86]|new[90]|new[91]	_	_
12-13	1706-1707	,	abstract[86]	giv[86]	_	_
12-14	1708-1717	abstracts	abstract[86]|abstract[92]	giv[86]|new[92]	coref	15-22[113_92]
12-15	1718-1722	from	abstract[86]|abstract[92]	giv[86]|new[92]	_	_
12-16	1723-1734	conferences	abstract[86]|abstract[92]|event	giv[86]|new[92]|new	_	_
12-17	1735-1736	,	abstract[86]|abstract[92]	giv[86]|new[92]	_	_
12-18	1737-1742	books	abstract[86]|abstract[92]|object	giv[86]|new[92]|new	_	_
12-19	1743-1744	,	abstract[86]|abstract[92]	giv[86]|new[92]	_	_
12-20	1745-1748	PhD	abstract[86]|abstract[92]|abstract|abstract[96]	giv[86]|new[92]|new|new[96]	_	_
12-21	1749-1755	theses	abstract[86]|abstract[92]|abstract[96]	giv[86]|new[92]|new[96]	_	_
12-22	1756-1760	were	_	_	_	_
12-23	1761-1769	excluded	_	_	_	_
12-24	1770-1771	.	_	_	_	_

#Text=2.3. Data Collection and Analysis
13-1	1772-1776	2.3.	_	_	_	_
13-2	1777-1781	Data	abstract|abstract[98]	new|new[98]	_	_
13-3	1782-1792	Collection	abstract[98]	new[98]	_	_
13-4	1793-1796	and	_	_	_	_
13-5	1797-1805	Analysis	abstract	new	_	_

#Text=Details of the manuscripts identified in the literature search were uploaded into a web-based system , which was used to manage the screening process and remove any duplicate citations .
14-1	1806-1813	Details	abstract[100]	new[100]	_	_
14-2	1814-1816	of	abstract[100]	new[100]	_	_
14-3	1817-1820	the	abstract[100]|object[101]	new[100]|giv[101]	_	_
14-4	1821-1832	manuscripts	abstract[100]|object[101]	new[100]|giv[101]	_	_
14-5	1833-1843	identified	abstract[100]|object[101]	new[100]|giv[101]	_	_
14-6	1844-1846	in	abstract[100]|object[101]	new[100]|giv[101]	_	_
14-7	1847-1850	the	abstract[100]|object[101]|abstract[103]	new[100]|giv[101]|giv[103]	_	_
14-8	1851-1861	literature	abstract[100]|object[101]|abstract|abstract[103]	new[100]|giv[101]|giv|giv[103]	_	_
14-9	1862-1868	search	abstract[100]|object[101]|abstract[103]	new[100]|giv[101]|giv[103]	_	_
14-10	1869-1873	were	_	_	_	_
14-11	1874-1882	uploaded	_	_	_	_
14-12	1883-1887	into	_	_	_	_
14-13	1888-1889	a	abstract[104]	new[104]	_	_
14-14	1890-1899	web-based	abstract[104]	new[104]	_	_
14-15	1900-1906	system	abstract[104]	new[104]	_	_
14-16	1907-1908	,	abstract[104]	new[104]	_	_
14-17	1909-1914	which	abstract[104]	new[104]	_	_
14-18	1915-1918	was	abstract[104]	new[104]	_	_
14-19	1919-1923	used	abstract[104]	new[104]	_	_
14-20	1924-1926	to	abstract[104]	new[104]	_	_
14-21	1927-1933	manage	abstract[104]	new[104]	_	_
14-22	1934-1937	the	abstract[104]|abstract[106]	new[104]|new[106]	_	_
14-23	1938-1947	screening	abstract[104]|abstract|abstract[106]	new[104]|new|new[106]	_	_
14-24	1948-1955	process	abstract[104]|abstract[106]	new[104]|new[106]	_	_
14-25	1956-1959	and	abstract[104]	new[104]	_	_
14-26	1960-1966	remove	abstract[104]	new[104]	_	_
14-27	1967-1970	any	abstract[104]|abstract[107]	new[104]|new[107]	_	_
14-28	1971-1980	duplicate	abstract[104]|abstract[107]	new[104]|new[107]	_	_
14-29	1981-1990	citations	abstract[104]|abstract[107]	new[104]|new[107]	_	_
14-30	1991-1992	.	_	_	_	_

#Text=In order to determine which studies would be included , three members of the review team independently screened the titles and abstracts of these articles and the full texts were retrieved based on our inclusion and exclusion criteria .
15-1	1993-1995	In	_	_	_	_
15-2	1996-2001	order	_	_	_	_
15-3	2002-2004	to	_	_	_	_
15-4	2005-2014	determine	_	_	_	_
15-5	2015-2020	which	abstract[108]	giv[108]	_	_
15-6	2021-2028	studies	abstract[108]	giv[108]	_	_
15-7	2029-2034	would	_	_	_	_
15-8	2035-2037	be	_	_	_	_
15-9	2038-2046	included	_	_	_	_
15-10	2047-2048	,	_	_	_	_
15-11	2049-2054	three	person[109]	new[109]	_	_
15-12	2055-2062	members	person[109]	new[109]	_	_
15-13	2063-2065	of	person[109]	new[109]	_	_
15-14	2066-2069	the	person[109]|organization[111]	new[109]|new[111]	_	_
15-15	2070-2076	review	person[109]|abstract|organization[111]	new[109]|new|new[111]	coref	20-17
15-16	2077-2081	team	person[109]|organization[111]	new[109]|new[111]	_	_
15-17	2082-2095	independently	_	_	_	_
15-18	2096-2104	screened	_	_	_	_
15-19	2105-2108	the	abstract[112]	new[112]	_	_
15-20	2109-2115	titles	abstract[112]	new[112]	_	_
15-21	2116-2119	and	_	_	_	_
15-22	2120-2129	abstracts	abstract[113]	giv[113]	_	_
15-23	2130-2132	of	abstract[113]	giv[113]	_	_
15-24	2133-2138	these	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-25	2139-2147	articles	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-26	2148-2151	and	_	_	_	_
15-27	2152-2155	the	abstract[115]	new[115]	_	_
15-28	2156-2160	full	abstract[115]	new[115]	_	_
15-29	2161-2166	texts	abstract[115]	new[115]	_	_
15-30	2167-2171	were	_	_	_	_
15-31	2172-2181	retrieved	_	_	_	_
15-32	2182-2187	based	_	_	_	_
15-33	2188-2190	on	_	_	_	_
15-34	2191-2194	our	person|abstract[120]	giv|giv[120]	ana	20-1
15-35	2195-2204	inclusion	abstract|abstract[118]|abstract[120]	giv|giv[118]|giv[120]	_	_
15-36	2205-2208	and	abstract[118]|abstract[120]	giv[118]|giv[120]	_	_
15-37	2209-2218	exclusion	abstract[118]|person|abstract[120]	giv[118]|new|giv[120]	_	_
15-38	2219-2227	criteria	abstract[120]	giv[120]	_	_
15-39	2228-2229	.	_	_	_	_

#Text=Two reviewers independently extracted the following data from each article :
16-1	2230-2233	Two	person[121]	new[121]	coref	18-4[144_121]
16-2	2234-2243	reviewers	person[121]	new[121]	_	_
16-3	2244-2257	independently	_	_	_	_
16-4	2258-2267	extracted	_	_	_	_
16-5	2268-2271	the	abstract[122]	new[122]	coref	18-10[146_122]
16-6	2272-2281	following	abstract[122]	new[122]	_	_
16-7	2282-2286	data	abstract[122]	new[122]	_	_
16-8	2287-2291	from	_	_	_	_
16-9	2292-2296	each	abstract[123]	giv[123]	_	_
16-10	2297-2304	article	abstract[123]	giv[123]	_	_
16-11	2305-2306	:	_	_	_	_

#Text=The country in which the study was conducted , number of participants , age of the participants at the time of inclusion , sex of the participants , amount of leucine administered , co-administration of other substances , sarcopenia evaluation methods , and the main and secondary outcomes of the study .
17-1	2307-2310	The	place[124]	new[124]	_	_
17-2	2311-2318	country	place[124]	new[124]	_	_
17-3	2319-2321	in	place[124]	new[124]	_	_
17-4	2322-2327	which	place[124]	new[124]	_	_
17-5	2328-2331	the	place[124]|abstract[125]	new[124]|giv[125]	coref	17-50[142_125]
17-6	2332-2337	study	place[124]|abstract[125]	new[124]|giv[125]	_	_
17-7	2338-2341	was	place[124]	new[124]	_	_
17-8	2342-2351	conducted	place[124]	new[124]	_	_
17-9	2352-2353	,	_	_	_	_
17-10	2354-2360	number	abstract[126]	new[126]	_	_
17-11	2361-2363	of	abstract[126]	new[126]	_	_
17-12	2364-2376	participants	abstract[126]|person	new[126]|new	coref	17-16[129_0]
17-13	2377-2378	,	_	_	_	_
17-14	2379-2382	age	abstract[128]	giv[128]	_	_
17-15	2383-2385	of	abstract[128]	giv[128]	_	_
17-16	2386-2389	the	abstract[128]|person[129]	giv[128]|giv[129]	coref	17-26[132_129]
17-17	2390-2402	participants	abstract[128]|person[129]	giv[128]|giv[129]	_	_
17-18	2403-2405	at	abstract[128]	giv[128]	_	_
17-19	2406-2409	the	abstract[128]	giv[128]	_	_
17-20	2410-2414	time	abstract[128]	giv[128]	_	_
17-21	2415-2417	of	abstract[128]	giv[128]	_	_
17-22	2418-2427	inclusion	abstract[128]|person	giv[128]|giv	_	_
17-23	2428-2429	,	_	_	_	_
17-24	2430-2433	sex	abstract[131]	new[131]	_	_
17-25	2434-2436	of	abstract[131]	new[131]	_	_
17-26	2437-2440	the	abstract[131]|person[132]	new[131]|giv[132]	coref	21-17[0_132]
17-27	2441-2453	participants	abstract[131]|person[132]	new[131]|giv[132]	_	_
17-28	2454-2455	,	_	_	_	_
17-29	2456-2462	amount	abstract[133]	new[133]	_	_
17-30	2463-2465	of	abstract[133]	new[133]	_	_
17-31	2466-2473	leucine	abstract[133]|substance[134]|substance[135]	new[133]|giv[134]|giv[135]	_	_
17-32	2474-2486	administered	abstract[133]|substance[134]|substance[135]	new[133]|giv[134]|giv[135]	_	_
17-33	2487-2488	,	abstract[133]|substance[135]	new[133]|giv[135]	_	_
17-34	2489-2506	co-administration	abstract[133]|substance[135]|person[136]	new[133]|giv[135]|new[136]	_	_
17-35	2507-2509	of	abstract[133]|substance[135]|person[136]	new[133]|giv[135]|new[136]	_	_
17-36	2510-2515	other	abstract[133]|substance[135]|person[136]|substance[137]	new[133]|giv[135]|new[136]|new[137]	_	_
17-37	2516-2526	substances	abstract[133]|substance[135]|person[136]|substance[137]	new[133]|giv[135]|new[136]|new[137]	_	_
17-38	2527-2528	,	abstract[133]|substance[135]	new[133]|giv[135]	_	_
17-39	2529-2539	sarcopenia	abstract[133]|substance[135]|abstract|abstract[140]	new[133]|giv[135]|giv|giv[140]	_	_
17-40	2540-2550	evaluation	abstract[133]|substance[135]|abstract|abstract[140]	new[133]|giv[135]|new|giv[140]	_	_
17-41	2551-2558	methods	abstract[133]|substance[135]|abstract[140]	new[133]|giv[135]|giv[140]	_	_
17-42	2559-2560	,	_	_	_	_
17-43	2561-2564	and	_	_	_	_
17-44	2565-2568	the	abstract[141]	new[141]	_	_
17-45	2569-2573	main	abstract[141]	new[141]	_	_
17-46	2574-2577	and	abstract[141]	new[141]	_	_
17-47	2578-2587	secondary	abstract[141]	new[141]	_	_
17-48	2588-2596	outcomes	abstract[141]	new[141]	_	_
17-49	2597-2599	of	abstract[141]	new[141]	_	_
17-50	2600-2603	the	abstract[141]|abstract[142]	new[141]|giv[142]	coref	20-8[154_142]
17-51	2604-2609	study	abstract[141]|abstract[142]	new[141]|giv[142]	_	_
17-52	2610-2611	.	_	_	_	_

#Text=Any disagreement between the reviewers regarding the papers and data extracted from them was resolved by the third author .
18-1	2612-2615	Any	abstract[143]	new[143]	_	_
18-2	2616-2628	disagreement	abstract[143]	new[143]	_	_
18-3	2629-2636	between	abstract[143]	new[143]	_	_
18-4	2637-2640	the	abstract[143]|person[144]	new[143]|giv[144]	_	_
18-5	2641-2650	reviewers	abstract[143]|person[144]	new[143]|giv[144]	_	_
18-6	2651-2660	regarding	abstract[143]|person[144]	new[143]|giv[144]	_	_
18-7	2661-2664	the	abstract[143]|person[144]|object[145]	new[143]|giv[144]|new[145]	_	_
18-8	2665-2671	papers	abstract[143]|person[144]|object[145]	new[143]|giv[144]|new[145]	_	_
18-9	2672-2675	and	abstract[143]|person[144]	new[143]|giv[144]	_	_
18-10	2676-2680	data	abstract[143]|person[144]|abstract[146]	new[143]|giv[144]|giv[146]	ana	18-13[0_146]
18-11	2681-2690	extracted	abstract[143]|person[144]|abstract[146]	new[143]|giv[144]|giv[146]	_	_
18-12	2691-2695	from	abstract[143]|person[144]|abstract[146]	new[143]|giv[144]|giv[146]	_	_
18-13	2696-2700	them	abstract[143]|person[144]|abstract[146]|abstract	new[143]|giv[144]|giv[146]|giv	_	_
18-14	2701-2704	was	_	_	_	_
18-15	2705-2713	resolved	_	_	_	_
18-16	2714-2716	by	_	_	_	_
18-17	2717-2720	the	person[148]	new[148]	coref	22-24[189_148]
18-18	2721-2726	third	person[148]	new[148]	_	_
18-19	2727-2733	author	person[148]	new[148]	_	_
18-20	2734-2735	.	_	_	_	_

#Text=2.4. Assessment of Bias
19-1	2736-2740	2.4.	_	_	_	_
19-2	2741-2751	Assessment	abstract[149]	new[149]	coref	21-26[176_149]
19-3	2752-2754	of	abstract[149]	new[149]	_	_
19-4	2755-2759	Bias	abstract[149]|person	new[149]|new	_	_

#Text=We assessed the risk of bias in each randomised and placebo-controlled study according to the Cochrane Review guidelines , which cover the following bias domains :
20-1	2760-2762	We	person	giv	_	_
20-2	2763-2771	assessed	_	_	_	_
20-3	2772-2775	the	abstract[152]	new[152]	_	_
20-4	2776-2780	risk	abstract[152]	new[152]	_	_
20-5	2781-2783	of	abstract[152]	new[152]	_	_
20-6	2784-2788	bias	abstract[152]|abstract	new[152]|new	coref	20-24
20-7	2789-2791	in	abstract[152]	new[152]	_	_
20-8	2792-2796	each	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
20-9	2797-2807	randomised	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
20-10	2808-2811	and	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
20-11	2812-2830	placebo-controlled	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
20-12	2831-2836	study	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
20-13	2837-2846	according	_	_	_	_
20-14	2847-2849	to	_	_	_	_
20-15	2850-2853	the	abstract[157]	giv[157]	_	_
20-16	2854-2862	Cochrane	person|abstract[157]	giv|giv[157]	_	_
20-17	2863-2869	Review	abstract|abstract[157]	giv|giv[157]	_	_
20-18	2870-2880	guidelines	abstract[157]	giv[157]	_	_
20-19	2881-2882	,	abstract[157]	giv[157]	_	_
20-20	2883-2888	which	abstract[157]	giv[157]	_	_
20-21	2889-2894	cover	abstract[157]	giv[157]	_	_
20-22	2895-2898	the	abstract[157]|abstract[159]	giv[157]|new[159]	_	_
20-23	2899-2908	following	abstract[157]|abstract[159]	giv[157]|new[159]	_	_
20-24	2909-2913	bias	abstract[157]|abstract|abstract[159]	giv[157]|giv|new[159]	coref	21-1[161_0]
20-25	2914-2921	domains	abstract[157]|abstract[159]	giv[157]|new[159]	_	_
20-26	2922-2923	:	_	_	_	_

#Text=Selection bias ( random sequence generation and allocation concealment ) , performance bias ( blinding of participants and personnel ) , detection bias ( blinding the outcome assessment ) , attrition bias ( incomplete outcome data ) , and reporting bias ( selective reporting ) .
21-1	2924-2933	Selection	abstract|abstract[161]	new|giv[161]	appos	21-4[163_161]
21-2	2934-2938	bias	abstract[161]	giv[161]	_	_
21-3	2939-2940	(	_	_	_	_
21-4	2941-2947	random	abstract[162]|abstract[163]|abstract[164]	new[162]|giv[163]|giv[164]	appos|appos	21-4[164_163]|21-8[166_164]
21-5	2948-2956	sequence	abstract[162]|abstract[163]|abstract[164]	new[162]|giv[163]|giv[164]	_	_
21-6	2957-2967	generation	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
21-7	2968-2971	and	abstract[164]	giv[164]	_	_
21-8	2972-2982	allocation	abstract[164]|abstract|abstract[166]	giv[164]|new|giv[166]	coref	21-12[168_166]
21-9	2983-2994	concealment	abstract[164]|abstract[166]	giv[164]|giv[166]	_	_
21-10	2995-2996	)	_	_	_	_
21-11	2997-2998	,	_	_	_	_
21-12	2999-3010	performance	abstract|abstract[168]	giv|giv[168]	appos	21-15[0_168]
21-13	3011-3015	bias	abstract[168]	giv[168]	_	_
21-14	3016-3017	(	_	_	_	_
21-15	3018-3026	blinding	abstract	giv	coref	21-22[174_0]
21-16	3027-3029	of	_	_	_	_
21-17	3030-3042	participants	person|person[171]	giv|giv[171]	coref	21-17[171_0]
21-18	3043-3046	and	person[171]	giv[171]	_	_
21-19	3047-3056	personnel	person[171]|person	giv[171]|new	_	_
21-20	3057-3058	)	_	_	_	_
21-21	3059-3060	,	_	_	_	_
21-22	3061-3070	detection	abstract|abstract[174]	new|giv[174]	coref	21-31[178_174]
21-23	3071-3075	bias	abstract[174]	giv[174]	_	_
21-24	3076-3077	(	_	_	_	_
21-25	3078-3086	blinding	_	_	_	_
21-26	3087-3090	the	abstract[176]	giv[176]	_	_
21-27	3091-3098	outcome	abstract|abstract[176]	new|giv[176]	coref	21-35
21-28	3099-3109	assessment	abstract[176]	giv[176]	_	_
21-29	3110-3111	)	_	_	_	_
21-30	3112-3113	,	_	_	_	_
21-31	3114-3123	attrition	abstract|abstract[178]	new|giv[178]	appos	21-34[180_178]
21-32	3124-3128	bias	abstract[178]	giv[178]	_	_
21-33	3129-3130	(	_	_	_	_
21-34	3131-3141	incomplete	abstract[180]	giv[180]	coref	21-40[181_180]
21-35	3142-3149	outcome	abstract|abstract[180]	giv|giv[180]	_	_
21-36	3150-3154	data	abstract[180]	giv[180]	_	_
21-37	3155-3156	)	_	_	_	_
21-38	3157-3158	,	_	_	_	_
21-39	3159-3162	and	_	_	_	_
21-40	3163-3172	reporting	abstract[181]	giv[181]	_	_
21-41	3173-3177	bias	abstract[181]	giv[181]	_	_
21-42	3178-3179	(	_	_	_	_
21-43	3180-3189	selective	_	_	_	_
21-44	3190-3199	reporting	_	_	_	_
21-45	3200-3201	)	_	_	_	_
21-46	3202-3203	.	_	_	_	_

#Text=The judgments were made independently by two researchers ( FM - M – A and R-F-V ) , with any discrepancies resolved with the third author ( OC ) .
22-1	3204-3207	The	abstract[182]	new[182]	_	_
22-2	3208-3217	judgments	abstract[182]	new[182]	_	_
22-3	3218-3222	were	_	_	_	_
22-4	3223-3227	made	_	_	_	_
22-5	3228-3241	independently	_	_	_	_
22-6	3242-3244	by	_	_	_	_
22-7	3245-3248	two	person[183]	new[183]	appos	22-10[0_183]
22-8	3249-3260	researchers	person[183]	new[183]	_	_
22-9	3261-3262	(	_	_	_	_
22-10	3263-3265	FM	person|person[185]	giv|giv[185]	appos	22-10[185_0]
22-11	3266-3267	-	person[185]	giv[185]	_	_
22-12	3268-3269	M	person[185]|person[186]	giv[185]|new[186]	_	_
22-13	3270-3271	–	person[185]|person[186]	giv[185]|new[186]	_	_
22-14	3272-3273	A	person[185]|person[186]	giv[185]|new[186]	_	_
22-15	3274-3277	and	person[185]	giv[185]	_	_
22-16	3278-3283	R-F-V	person[185]|abstract	giv[185]|new	_	_
22-17	3284-3285	)	_	_	_	_
22-18	3286-3287	,	_	_	_	_
22-19	3288-3292	with	_	_	_	_
22-20	3293-3296	any	abstract[188]	new[188]	_	_
22-21	3297-3310	discrepancies	abstract[188]	new[188]	_	_
22-22	3311-3319	resolved	abstract[188]	new[188]	_	_
22-23	3320-3324	with	abstract[188]	new[188]	_	_
22-24	3325-3328	the	abstract[188]|person[189]	new[188]|giv[189]	_	_
22-25	3329-3334	third	abstract[188]|person[189]	new[188]|giv[189]	_	_
22-26	3335-3341	author	abstract[188]|person[189]	new[188]|giv[189]	_	_
22-27	3342-3343	(	_	_	_	_
22-28	3344-3346	OC	abstract	new	_	_
22-29	3347-3348	)	_	_	_	_
22-30	3349-3350	.	_	_	_	_
